Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). In this educational program, these experts use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the NSCLC continuum, including patient selection, therapeutic sequencing, and toxicity management.
This educational activity is an archive of the live symposium held on February 19, 2026.
Target Audience
This educational activity is directed toward medical and thoracic oncologists, pulmonologists, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care practitioners involved in the management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the clinical importance of distinguishing between HER2 mutations, amplifications, and HER2 protein overexpression in managing advanced NSCLC
- Integrate current data supporting HER2-directed therapies to develop personalized treatment plans for patients with advanced NSCLC harboring HER2 alterations
- Examine the role of TROP2-targeted ADCs in advanced NSCLC with and without targetable genomic alterations
- Implement evidence-based strategies to prevent and manage adverse events linked to HER2- and TROP2-directed therapies in NSCLC
Jacob Sands, MD
Associate Chief, Lowe Center for Thoracic
Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Jazz Pharmaceuticals, Gilead, Merck, Novartis, Pfizer, Sanofi, Medtronic; Grant/Research Funding: Amgen, Harpoon, Novartis
Marina Chiara Garassino, MD
Professor of Medicine
Director, Thoracic Oncology Program
The University of Chicago Medical Center
Chicago, IL
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Aptitude Health, AstraZeneca, Astro,
Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IASLC,
Ideology, IO Biotech, Janssen Pharmaceuticals, Merck & Co, Mirati
Therapeutics, Natera, Novocure, Nuvalent, Nuvation, OncoHost, Pfizer,
Regeneron, Revolution Medicines, Roche, Summit, Takeda; Grant/Research
Funding: AIRC, AIFA, Fondazione Veronesi, Horizon 2020, Italian
Moh, TRANSCAN
Eric K. Singhi, MD
Thoracic Medical Oncologist
Assistant Professor
The University of Texas MD Anderson Cancer
Center
Houston, TX
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, GSK, Janssen, Lilly, Novocure, Nuvalent, Nuvation Bio, Regeneron, Roche, Sandoz; Grant/Research Funding: Rexanna’s Foundation for Fighting Lung Cancer
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
